243448-16-0

Basic information

• Product Name: 6,8-DIFLUORO-4-HYDROXYQUINOLINE
• Synonyms: BUTTPARK 30\09-65;6,8-DIFLUORO-4-HYDROXYQUINOLINE;4-HYDROXY-6,8-DIFLUOROQUINOLINE
• CAS NO: 243448-16-0
• Molecular Formula: C9H5F2NO
• Molecular Weight: 181.14
• Mol File: 243448-16-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 256.3°C at 760 mmHg
• Flash Point: 108.8°C
• Appearance: /
• Density: 1.387g/cm³
• Vapor Pressure: 0.0155mmHg at 25°C
• Refractive Index: 1.548
• PKA: 7.40±0.33(Predicted)
• CAS DataBase Reference: 6,8-DIFLUORO-4-HYDROXYQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6,8-DIFLUORO-4-HYDROXYQUINOLINE(243448-16-0)
• EPA Substance Registry System: 6,8-DIFLUORO-4-HYDROXYQUINOLINE(243448-16-0)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 243448-16-0(Hazardous Substances Data)

Usage

General Description

6,8-Difluoro-4-hydroxyquinoline is a chemical compound with the molecular formula C9H5F2NO. It is a fluorinated quinoline derivative that contains two fluorine atoms at positions 6 and 8, and a hydroxy group at position 4 in the quinoline ring. This chemical compound is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has been studied for its potential antimicrobial and antifungal properties, making it a valuable compound in the development of new drugs and pesticides. Additionally, it is known to exhibit moderate cytotoxicity against cancer cell lines, which further expands its potential applications in the field of oncology research and drug development.

InChI:InChI=1/C9H5F2NO/c10-5-3-6-8(13)1-2-12-9(6)7(11)4-5/h1-4H,(H,12,13)

Upstream product

• 1071541-70-2 5-[(3,5-difluoro-phenylamino)-methylene]-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 367-25-9 2,4-difluorophenylamine 
• 372-39-4 3,5-difluoroaniline 
• 2033-24-1 cycl-isopropylidene malonate 

Downstream Products

• 1384272-31-4 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(5-fluoro-2-methylphenyl)urea 
• 1384272-32-5 1-(2-chloro-5-(trifluoromethyl)phenyl)-3-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)urea 
• 1384272-33-6 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(4-isopropylphenyl)urea 
• 1384272-34-7 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(3,4-dimethylphenyl)urea 
• 239463-89-9 4-chloro-6,8-difluoro-quinoline 
• 1384272-25-6 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(2-(trifluoromethoxy)phenyl)urea 
• 1384272-26-7 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(4-(trifluoromethoxy)phenyl)urea 
• 1384272-27-8 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(2-(trifluoromethyl)phenyl)urea 
• 1384272-28-9 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(4-(trifluoromethyl)phenyl)urea 
• 1384272-29-0 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(2-fluorophenyl)urea 
• 1384272-30-3 1-(3-chloro-2-fluorophenyl)-3-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)urea 
• 577692-34-3 4-bromo-6,8-difluoroquinoline 

Relevant articles and documents

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

AURORA KINASE MODULATORS AND METHOD OF USE

The present invention relates to chemical compounds having a general formula I {INSERT STRUCTURE HERE} wherein A1-8, D,, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities

A simple two-step synthesis method was used to make 51 B-ring-substituted 4-hydroxyquinolines allowing analysis of the effect of ring substitutions on inhibition of growth of chloroquine sensitive and resistant strains of Plasmodium falciparum, the dominant cause of malaria morbidity. Substituted quinoline rings other than the 7-chloroquinoline ring found in chloroquine were found to have significant activity against the drug-resistant strain of P. falciparum W2.